Share-based Payment Arrangement, Expense of Astria Therapeutics, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Astria Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Astria Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,308,000, a 25% increase year-over-year.
  • Astria Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $15,901,000.
  • Astria Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $13,042,000, a 107% increase from 2023.
  • Astria Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6,314,000, a 39% increase from 2022.
  • Astria Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,554,000, a 35% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Astria Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $15,901,000 $4,308,000 +$874,000 +25% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $15,027,000 $4,351,000 +$900,000 +26% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $14,127,000 $3,839,000 +$1,085,000 +39% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $13,042,000 $3,403,000 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $3,434,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $3,451,000 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $2,754,000 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2020 $1,390,000 $305,000 +$20,000 +7% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $1,370,000 $375,000 -$3,000 -0.79% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q2 2020 $1,373,000 $371,000 -$70,000 -16% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $1,443,000 $339,000 -$69,000 -17% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2020 2020 Q1
Q4 2019 $1,512,000 $285,000 -$145,000 -34% 01 Oct 2019 31 Dec 2019 10-K/A 19 Apr 2021 2020 FY
Q3 2019 $1,657,000 $378,000 -$38,000 -9.1% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $1,695,000 $441,000 -$5,000 -1.1% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $1,700,000 $408,000 -$71,000 -15% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q4 2018 $1,771,000 $430,000 -$76,000 -15% 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
Q3 2018 $1,847,000 $416,000 -$99,000 -19% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $1,946,000 $446,000 -$35,000 -7.3% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $1,981,000 $479,000 -$26,000 -5.1% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $2,007,000 $506,000 -$79,000 -14% 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $2,086,000 $515,000 +$5,000 +0.98% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $2,081,000 $481,000 -$36,000 -7% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $2,117,000 $505,000 -$43,000 -7.8% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $2,160,000 $585,000 +$70,000 +14% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2018 2017 FY
Q3 2016 $2,090,000 $510,000 +$22,000 +4.5% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $2,068,000 $517,000 +$163,000 +46% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $1,905,000 $548,000 +$247,000 +82% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q4 2015 $1,658,000 $515,000 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2018 2017 FY
Q3 2015 $488,000 +$256,000 +110% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $354,000 +$126,000 +55% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $301,000 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q3 2014 $232,000 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $228,000 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2

Astria Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $13,042,000 +$6,728,000 +107% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $6,314,000 +$1,760,000 +39% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $4,554,000 +$1,193,000 +35% 01 Jan 2022 31 Dec 2022 10-K 04 Mar 2024 2023 FY
2021 $3,361,000 +$1,971,000 +142% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $1,390,000 -$122,000 -8.1% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $1,512,000 -$259,000 -15% 01 Jan 2019 31 Dec 2019 10-K/A 19 Apr 2021 2020 FY
2018 $1,771,000 -$236,000 -12% 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
2017 $2,007,000 -$153,000 -7.1% 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
2016 $2,160,000 +$502,000 +30% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2018 2017 FY
2015 $1,658,000 +$761,000 +85% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018 2017 FY
2014 $897,000 +$554,000 +162% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $343,000 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.